Comparing Gemcitabine Alone to Gemcitabine with Oxaliplatin in Pancreatic Cancer Treatment
Author Information
Author(s): Heinrich Stefan, Pestalozzi Bernhard, Lesurtel Mickael, Berrevoet Frederik, Laurent Stéphanie, Delpero Jean-Robert, Raoul Jean-Luc, Bachellier Phillippe, Dufour Patrick, Moehler Markus, Weber Achim, Lang Hauke, Rogiers Xavier, Clavien Pierre-Alain
Primary Institution: University Hospital of Zurich
Hypothesis
Does neoadjuvant chemotherapy improve outcomes in patients with resectable pancreatic cancer compared to adjuvant chemotherapy alone?
Conclusion
The NEOPAC study aims to determine the efficacy of neoadjuvant chemotherapy in improving survival rates for patients with resectable pancreatic cancer.
Supporting Evidence
- Neoadjuvant chemotherapy has shown a median survival of 26.5 months in previous trials.
- Adjuvant chemotherapy is the standard of care but many patients cannot receive it due to surgical morbidity.
- Neoadjuvant chemotherapy can improve the nutritional status of patients before surgery.
Takeaway
This study is trying to find out if giving chemotherapy before surgery helps people with pancreatic cancer live longer and healthier.
Methodology
This is a randomized controlled phase III trial comparing standard treatment with neoadjuvant chemotherapy followed by surgery.
Potential Biases
Potential selection bias due to strict inclusion and exclusion criteria.
Limitations
The study may not account for all variables affecting patient outcomes, and strict eligibility criteria may limit generalizability.
Participant Demographics
Patients must be at least 18 years old with resectable adenocarcinoma of the pancreatic head.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website